Differential phosphoprotein levels and pathway analysis identify the transition mechanism of LNCaP cells into androgen-independent cells

Prostate

Volumn 70, Issue 5, 2010, Pages 508-517

  Wang, Hui Qing ^a   Yang, Bo ^a   Xu, Chuan Liang ^a   Wang, Lin Hui ^a   Zhang, Yu Xi ^a   Xu, Bin ^a   Ji, Jia Tao ^a   Sun, Ying Hao ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Androgen independence; Mechanism; Phosphoproteins; Prostate cancer

Indexed keywords

PHOSPHOPROTEIN; HEAT SHOCK PROTEIN 27; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN P53;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; CELL STRAIN LNCAP; CONTROLLED STUDY; DATA BASE; GENE EXPRESSION REGULATION; HORMONE DEPENDENCE; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOLECULAR MECHANICS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; WESTERN BLOTTING; CHEMISTRY; IMMUNOBLOTTING; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; PROTEOMICS; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

CELL LINE, TUMOR; HSP27 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOBLOTTING; MALE; MAP KINASE SIGNALING SYSTEM; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHOPROTEINS; PROSTATIC NEOPLASMS; PROTEOMICS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77949900754     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21085     Document Type: Article

References (22)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer statistics 2006. CA Cancer J Clin 2006;56(2):106-130.
2. McGarvey TW, Meng RD, Johnson O, El-Deiry W, Malkowicz SB. Growth inhibitory effect of p21 and p53 containing adenoviruses on transitional cell carcinoma cell lines in vitro and in vivo. Urol Oncol 2001;6(4):155-162. (Pubitemid 32552016)
3. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502-1512. (Pubitemid 39315317)
4. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CM, Murphy KC. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points. J Clin Oncol 1996;14(6):1756-1764. (Pubitemid 26185452)
5. Scher HI, Eisenberger M, D'Amico AV, Halabi S, Small EJ, Morris M, Kattan MW, Roach M, Kantoff P, Pienta KJ, Carducci MA, Agus D, Slovin SF, Heller G, Kelly WK, Lange PH, Petrylak D, Berg W, Higano C, Wilding G, Moul JW, Partin AN, Logothetis C, Soule HR. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: Recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 2004;22(3):537-556. (Pubitemid 41079783)
6. Schröder FH. Progress in understanding androgen-independent prostate cancer (AIPC): A review of potential endocrine-mediated mechanisms. Eur Urol 2008;53(6):1129-1137.
7. Vermeulen K, Berneman ZN, Van Bockstaele DR. Cell cycle and apoptosis. Cell Prolif 2003;36(3):165-175.
8. Wang LG, Liu XM, Kreis W, Budman DR. Phosphorylation/dephosphorylation of androgen receptor as a determinant of androgen agonistic or antagonistic activity. Biochem Biophys Res Commun 1999;259(1):21-28. (Pubitemid 29263987)
9. Ghosh R, Gu G, Tillman E, Yuan J, Wang Y, Fazli L, Rennie PS, Kasper S. Increased expression and differential phosphorylation of stathmin may promote prostate cancer progression. Prostate 2007;67(10):1038-1052. (Pubitemid 46983334)
10. Culig Z, Hoffmann J, Erdel M, Eder IE, Hobisch A, Hittmair A, Bartsch G, Utermann G, Schneider MR, Parczyk K, Klocker H. Switch from antagonist to agonist of the androgen receptor-bicalutamide is associated with prostate tumourprogression in a new model system. Br J Cancer 1999;81:242-251. (Pubitemid 29423702)
11. Gustavsson H, Welén K, Damber JE. Transition of an androgen-dependent human prostate cancer cell line into an androgen-independent subline is associated with increased angiogenesis. Prostate 2005;62(4):364-373. (Pubitemid 40227488)
12. Jensen LJ, Kuhn M, Stark M, Chaffron S, Creevey C, Muller J, Doerks T, Julien P, Roth A, Simonovic M, Bork P, von Mering C. STRING 8 - A global view on proteins and their functional interactions in 630 organisms. Nucleic Acids Res 2009;37:D412-D416.
13. Von Mering C, Huynen M, Jaeggi D, Schmidt S, Bork P, Snel B. STRING: A database of predicted functional associations between proteins. Nucleic Acids Res 2003;31(1):258-261. (Pubitemid 36150379)
14. Gao M, Ossowski L, Ferrari AC. Activation of Rb and decline in androgen receptor protein precede retinoic acid-induced apoptosis in androgen-dependent LNCaP cells and their androgen-independent derivative. J Cell Physiol 1999;179(3):336-346. (Pubitemid 29203158)
15. Kokontis JM, Hay N, Liao S. Progression of LNCaP prostate tumor cells during androgen deprivation: Hormone-independent growth, repression of proliferation by androgen, and role for p27kip1 in androgen-induced cell cycle arrest. Mol Endocrinol 1998;12(7):941-953. (Pubitemid 30660662)
16. Lu S, Tsai SY, Tsai MJ. Molecular mechanisms of androgen independent growth of human prostate cancer LNCaP-Ai cells. Endocrinology 1999;140(11):5054-5059.
17. Rocchi P, So A, Kojima S, Signaevsky M, Beraldi E, Fazli L, Hurtado-Coll A, Yamanaka K, Gleave M. Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res 2004;64(18):6595-6602. (Pubitemid 39297919)
18. Hino M, Kurogi K, Okubo MA, Murata-Hori M, Hosoya H. Small heat shock protein 27 (HSP27) associates with tubulin/microtubules in HeLa cells. Biochem Biophys Res Commun 2000;271(1):164-169. (Pubitemid 30444872)
19. O'Callaghan-Sunol C, Gabai VL, Sherman MY. HSP27 Modulates p53 Signaling and Suppresses Cellular Senescence. Cancer Res 2007;67(24):11779-11788.
20. Zheng C, Lin Z, Zhao ZJ, Yang Y, Niu H, Shen X. MAPK-activated protein kinase-2 (MK2)-mediated formation and phosphorylation-regulated dissociation of the signal complex consisting of p38, MK2, Akt, and HSP27. J Biol Chem 2006;281(48):37215-37226. (Pubitemid 46042191)
21. Fuchs D, Berges C, Opelz G, Daniel V, Naujokat C. Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells. J Cell Biochem 2008;103(1):270-283.
22. Navas TA, Nguyen AN, Hideshima T, Reddy M, Ma JY, Haghnazari E, Henson M, Stebbins EG, Kerr I, O'Young G, Kapoun AM, Chakravarty S, Mavunkel B, Perumattam J, Luedtke G, Dugar S, Medicherla S, Protter1 AA, Schreiner GF, Anderson KC, Higgins LS. Inhibition of p38 a MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating HSP27, Bcl-XL, Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo. Leukemia 2006;20(6):1017-1027. (Pubitemid 43797292)